Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wattana Karnpaet PCLBKK:NEW 75 EBITDA Margin % is 19.45% as of Mar. 2026, which is 28% above its 10-year median of 15.17. GuruFocus rates BKK:NEW with a GF Score™ of 75/100 and a GF Value™ of ฿96.93 (Fairly Valued). The stock has 1 warning sign investors should review. Among 664 Healthcare Providers & Services companies, Wattana Karnpaet PCL ranks better than 79.82% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Wattana Karnpaet PCL EBITDA Margin % Related Terms
Wattana Karnpaet PCL EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Wattana Karnpaet PCL's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:NEW vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Wattana Karnpaet PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wattana Karnpaet PCL EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Wattana Karnpaet PCL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Wattana Karnpaet PCL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wattana Karnpaet PCL (BKK:NEW) has a EBITDA Margin % of 19.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wattana Karnpaet PCL and its competitors. This is 28% above median its historical median of 15.17. Over the past decade, Wattana Karnpaet PCL's EBITDA Margin % has ranged from 13.01 to 31.50. According to the industry distribution chart, Wattana Karnpaet PCL ranks #134 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 20.2%.
Is Wattana Karnpaet PCL's EBITDA Margin % too high?
Wattana Karnpaet PCL's current EBITDA Margin % of 19.45% is 28% above median its 10-year median of 15.17. Over the past 10 years, this metric has ranged from a low of 13.01 to a high of 31.50. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Wattana Karnpaet PCL's value of 19.45% is 90.5% above this industry median. Based on the distribution chart, Wattana Karnpaet PCL ranks #134 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Wattana Karnpaet PCL has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wattana Karnpaet PCL's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Wattana Karnpaet PCL ranks #134 out of 664 companies for EBITDA Margin %. This places Wattana Karnpaet PCL in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Wattana Karnpaet PCL's value of 19.45% is 90.5% above this benchmark. Historically, Wattana Karnpaet PCL's own EBITDA Margin % has ranged from 13.01 to 31.50 over the past decade. While the company's 10-year median is 15.17 vs. the industry median of 10.21, Wattana Karnpaet PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wattana Karnpaet PCL's current EBITDA Margin % of 19.45% is 90.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wattana Karnpaet PCL and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wattana Karnpaet PCL's current EBITDA Margin % is 19.45%, which is 28% above median its own 10-year median of 15.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wattana Karnpaet PCL stock overvalued right now?
Based on GuruFocus' analysis, Wattana Karnpaet PCL (BKK:NEW) is currently considered Fairly Valued. The stock's GF Value™ is ฿96.93, compared to a current price of ฿104.00 — trading 7.3% above its estimated fair value. The current EBITDA Margin % is 19.45%, which is 28% above median its 10-year median of 15.17 and 90.5% above the Healthcare Providers & Services industry median of 10.21. Wattana Karnpaet PCL's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Wattana Karnpaet PCL (BKK:NEW), the current EBITDA Margin % is 19.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wattana Karnpaet PCL (BKK:NEW) Overvalued in 2026?
Based on GuruFocus' analysis, Wattana Karnpaet PCL stock appears to be overvalued.
The current stock price of ฿104.00 is trading 7.3% above its estimated GF Value™ of ฿96.93.
GuruFocus considers Wattana Karnpaet PCL to be Fairly Valued.
Key valuation signals for BKK:NEW:
EBITDA Margin %: 19.45% (28% above median its 10-year median of 15.17)
GF Value™: ฿96.93 vs. price of ฿104.00 (7.3% above fair value)
Industry Position: 90.5% above the Healthcare Providers & Services median (#134 of 664)
No single metric tells the full story. See the BKK:NEW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wattana Karnpaet PCL is engaged in the operation of a hospital under the name North Eastern Wattana Hospital. It has a single segment of operation, namely the hospital and medical trading business. The company earns revenue from hospital, revenue from sales of medicines, and revenue from hospital rooms, which are derived from the provision of services to various types and a large number of customers. Geographically, the company's operations are carried out in Thailand.
75GF Score
Get the complete analysis for BKK:NEW
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NEW has been successfully added to your 
